CIRM as a Lobbyist: Mission Creep, Industry Ties and Board Conflicts
The California stem cell agency is once again going to consider its position and lobbying efforts on behalf of industry-supported federal legislation dealing with development of generic biotech therapies.
The topic is expected to be placed on the June agenda of the CIRM board because of a question about whether the board's endorsement of the bill on May …
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.